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The expression fCD45 polypeptides, a phosphotyrosine phosphatase complex specific of leukocytes, has been i vesti- 
gated in both resting and activated neutrophils by using anti-CD45 monoelonal antibodies (MAb) which specif ally 
recognize different polypeptide components of the CIM5 molecular complex. Polypeptides of 180 and 130-150 kDa were 
equally precipitated by either a conventional CD45 MAb recognizing an antigenic determinant shared by the four CD45 
glycoproteins (220, 205, 190 and 180 kDa) or by the anti-180 kDa UCHLI MAb. These polypeptides were ov xpressed 
on neutrophil plasma membranes after degranulatory stimulation. Conversely, neither the anti-220 kDa CD45R nor anti- 
220/205/190 kDa MAb reacted with CD45 molecules from resting oractivated neutrophils. Furthermore, permeabiliza- 
tion analysis and comparative immunoprecipitation studies with different anti-CD45 MAb from fractions enriched in 
various neutrophil granules rev aled that CD45 polypeptides (180and 130-150 kDa) from internal granules are antigenic 
and biochemically identical to those xpressed on plasma membrane. 
Differentiation a tigen; Polypeptide, CD45; Antigen specificity; Phosphotyrosine phosphatase; (Human ne trophil) 
1. INTRODUCTION 
CD45 (leukocyte common antigen, LCA, T200, 
Ly5) is a pan-leukocyte phosphotyrosine phos- 
phatase glycoprotein complex showing a marked 
biochemical and antigenic heterogeneity [1-4]. 
This heterogeneity is due to the existence of cell- 
type-specific alternative splicing from a common 
precursor mRNA that generates several CD45 
mature mRNAs coding for proteins with distinct 
amino acid content of the N-terminal regions 
[5-9]. Variable carbohydrate composition also 
contributes to the heterogeneity found within the 
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CD45 molecular complex [10,11]. In human 
peripheral blood lymphocytes (PBL), CD45 is 
composed of four glycoproteins of 220, 205, 190 
and 180 kDa, which are differentially expressed by 
distinct cell lineages [12]. We have previously 
characterized on PBL four different histological 
and biochemical specificities of CD45 defined by 
distinct anti-CD45 MAb [13]: (i) MAb recognizing 
the four CD45 glycoproteins (conventional pan- 
leukocyte CD45 specificity); (ii) MAb directed to 
the 220 kDa CD45 component (CD45R specifici- 
ty); (iii) MAb recognizing the 220, 205 and 
190 kDa CD45 components; and (iv) MAb specific 
for the 180 kDa CD45 polypeptide. 
We have also recently reported the overexpres- 
sion upon activation and the intracellular location 
of CD45 in human neutrophils [14], but in those 
studies the identity of CD45 components expressed 
on these cells was not established. 
Here, the antigenic and biochemical nature of 
the distinct CD45 polypeptides expressed on 
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p lasma membrane  and internal  granules o f human 
neutroph i l s  has been invest igated.  
2. MATERIALS  AND METHODS 
2.1. Monoclonal antibodies 
The D3/9 and RP1/ l l  MAb are specific for conventional 
CD45 and CD45R, respectively [13,15]. MC5/2 MAb, directed 
against an epitope shared by the three CD45 polypeptides of 
largest size, displays identical reactivity to that of PD7/26/16 
MAb, which originally defined such specificity [13,16]. The 
UCHLI MAb recognizes an epitope only present on the 
180 kDa CD45 polypeptide, and was kindly provided by Dr 
P.C.L. Beverley [13,17]. P3X63 IgG1 myeloma culture super- 
natant was used as negative control. 
2.2. Cells 
Cells were obtained from heparinized venous blood of nor- 
mal volunteers. PBL were isolated by Ficoll Hypaque (Phar- 
macia, Uppsaia) centrifugation. Neutrophils were isolated by 
subtraction of PBL as indicated above followed by sedimenta- 
tion of erythrocytes in 1.3070 (w/v) dextran at room 
temperature. Residual erythrocytes were removed by hypotonic 
lysis. 
2.3. Neutrophil activation 
Neutrophils were resuspended at 3 × 106 cells/ml in cold 
Hepes/glucose buffer (150 mM NaC1, 5 mM KOH, 10 mM 
Hepes, 1.2 mM MgCl2, 1.3 mM CaCl2, 5.5 mM glucose; pH 
7.5) and incubated at 37°C with activating agent for 15 rain. 
The Ca 2+ ionophore A23187 was employed at 3 × 10 -6 M, 
fMLP at 10 -7 M, and PMA at 20 ng/ml. All reagents were 
from Sigma (St. Louis, MO). Cells held at 4°C or incubated at 
37°C in the absence of any stimulus were run in parallel. 
2.4. FACS analysis 
Flow cytometry analysis was performed on an EPICS-C 
cytofluorometer (Coulter Scientific, Harpenden, England). 
Cells were incubated at 4°C with 100/A MAb-containing 
culture supernatants, followed by washing and labeling with 
fluorescein isothiocyanate (FITC)-labeled goat anti-mouse Ig. 
Fluorescence data were collected on a log scale and were con- 
verted to a linear scale for quantitative stimation. Specific 
linear fluorescence was obtained by subtracting background 
fluorescence produced by the negative control myeloma P3X63. 
2.5. Cell permeabilization 
Neutrophils were permeabilized as in [18]. Briefly, after cell 
fixation with 4°70 paraformaldehyde, 0.2% glutaraldehyde, 
0.1 M sodium phosphate (pH 7.3) for 15 min at 4°C, and 
reduction in phosphate-buffered saline (PBS) containing 0.1070 
freshly prepared NaBH4 for 10 min, neutrophils were incubated 
in PBS, 0.1070 Triton X-100 for 15 min at 20°C. Then cells were 
washed twice with PBS containing 10% fetal calf serum, 
10 mM Hepes, 5 mM EDTA and subjected to labeling with 
MAb and FITC-labeled goat anti-mouse Ig as described above. 
2.6. Subcellular fractionation of neutrophils 
Neutrophils were fractionated as described [19]. Briefly, 
postnuclear supernatant w s layered onto a 15-40% (w/w) con- 
tinuous sucrose gradient, and centrifuged at 76000 x g for 
15 min at 4°C. Subsequently, fractions were collected by pump- 
ing 60070 sucrose into the bottom. Each fraction was diluted 
with 50 mM Tris-HC1, 100 mM NaC1 (pH 8.0) and centrifuged 
at 70000 x g for 90 min at 4°C. Pellets, representing the mem- 
branes of each fraction, were resuspended in 50 mM Tris-HCl 
(pH 7.5) and stored at -70°C. For radiolabeling experiments, 
membrane proteins were solubilized in borate saline buffer 
(0.01 M sodium borate, 0.14 M NaC1; pH 8.2) containing 0.2070 
Triton X-100. 
2.7. Radiolabeling, immunoprecipitation a d electrophoresis 
Solubilized membrane proteins (50/~g) from the subcellular 
fractions or cell suspensions were radioiodinated in solution 
with chloroglycoluril (Iodo-Gen, Pierce, Rockford, IL). Cells 
were lysed in PBS (pH 7.4) containing 1070 Triton X-100, 1070 
hemoglobin and 1 mM PMSF. For immunoprecipitation, equal 
amounts of input radioactivity of ~25I-labeled proteins from 
each subcellular fraction or cell lysates were mixed with 100/zl 
MAb-containing culture supernatants. To isolate immune com- 
plexes 100/~1 of 187.1 anti-mouse x-chain MAb followed by 
30/zl protein A from S. aureus coupled to Sepharose (Phar- 
macia) were added. Immunoprecipitates were processed as in 
[20], and samples were subjected to SDS-7070 PAGE and 
autoradiography. 
3. RESULTS 
To  determine  the ant igenic  and b iochemica l  
ident i ty  o f  CD45 prote ins expressed on human 
neutrophi ls ,  immunoprec ip i ta t ion  exper iments  
were carr ied out  with 125I-labeled neutroph i l  
lysates using d i f ferent  ant i -CD45 MAb ( f ig . lA ) .  
On ly  po lypept ides  o f  180 and 130-150 kDa were 
prec ip i tated f rom neutroph i l s  by both  conven-  
t iona l  ant i -CD45 D3/9  MAb and anti -180 kDa 
UCHL1 MAb ( f ig . lA ,  lanes 1,3, respect ively).  In 
contrast ,  no CD45 po lypept ides  were prec ip i tated 
f rom neutroph i l s  by M.Ab recogniz ing the 
220/205/190  kDa CD45 components  (MC5/2  
MAb)  or  by the ant i -CD45R MAb specif ic for  the 
220 kDa po lypept ide  (RP1/11  MAb)  (fig. 1A, lanes 
2,4, respect ively).  P rec ip i tat ions  f rom 12~I-labeled 
PBL ,  where the four  dist inct b iochemica l  patterns 
were establ ished,  were also inc luded for  com-  
par i son  (fig. 1B). 
The  react iv i ty  o f  the d i f ferent  ant i -CD45 MAb 
towards  neutrophi ls  and PBL  was also studied by 
f low cytometry .  Neut roph i l s  were equal ly  react ive 
wi th  convent iona l  CD45 D3/9  and anti -180 kDa 
UCHL1 MAb ( f ig .2A,C,  respect ively),  whereas  no 
sta in ing was observed with the other  two anti -  
CD45 MAb (MC5/2  and RP1/11  MAb)  ( f ig .2B,D,  
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Fig. 1. CD45 polypeptides precipitated by different anti-CD45 
MAb from human neutrophils and PBL. Neutrophil (A) or 
PBL (B) ~25I-labeled lysates were precipitated by conventional 
anti-CD45 D3/9 MAb (lanes 1), anti-220/205/190 kDa MC5/2 
MAb (lanes 2), anti-180 kDa UCHLI MAb (lanes 3), and anti- 
CD45R RP I / l l  MAb (lanes 4). Immune complexes were 
isolated as described in section 2, and reduced samples were 
subjected to SDS-7% PAGE and autoradiography. 
respectively). However, four clearly distinct reac- 
tivity patterns were defined by these MAb on PBL 
(fig.2E-n). 
Since we have previously reported that expres- 
sion of CD45 on neutrophil plasma membranes 
can increase as a result of a stimulus-dependent 
translocation event, we also studied the antigenici- 
ty of CD45 molecules upregulated by this process. 
As shown in table 1, a significant increase in CD45 
plasma membrane xpression was observed when 
neutrophils were stimulated with different degran- 
ulatory agents, as detected by staining with either 
D3/9 or UCHL1 MAb. On the other hand, stain- 
ing by MC5/2 or RP1/l l  MAb remained negative 
after neutrophil activation. Furthermore, only 
reactivity with either D3/9 or UCHLI MAb was 
detected when resting neutrophils were detergent- 
permeabilized toallow accessibility of CD45 inter- 
nal molecules (table 1). Immunoprecipitation ex-
periments on 125I-labeled cell lysates did not reveal 
qualitative differences between CD45 polypeptides 
on plasma membranes from either resting or ac- 
tivated neutrophils (not shown). 
To investigate further the identity of the in- 
tracellular proteins of CD45, subcellular f actiona- 
tion studies were performed on resting neutrophils. 
Subcellular fractions were obtained by rate zonal 
sedimentation a d fractionation was monitored by
using the enzymatic markers alkaline phosphatase 
(plasma membrane), gelatinase (tertiary granules), 
lysozyme (specific granules) and B-glucuronidase 
(azurophilic granules) as described in [14]. Mem- 
brane proteins from the distinct subcellular frac- 
tions were radiolabeled and comparative immuno- 
precipitation experiments were carried out. As 
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Fig.2. Immunofluorescence flow cytometry analysis of cells stained with different anti-CD45 MAb. Neutrophils (A-D) or PBL (E-H) 
were stained by D3/9 (A,E), MC5/2 (B,F), UCHL1 (C,G), or RPI/11 MAb (D,H) and analyzed as described in the text; Dotted lines 
correspond to staining with P3X63 negative control. 
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Table 1 
Expression of CD45 biochemical specificities on human neutrophils upon incubation with different 
stimulating agents or upon permeabilization treatment 
June 1989 
MAb CD Molecular mass Treatment 
(kDa) 
4°C 37°C PMA fMLP Ca 2+ Permea- 
ionophore bilization 
D3/9 (CD45) 220,205,190,180 57 ± 9 93 ± 16 107 ± 19 117 + 9 117 ± 18 125 ±20 
MC5/2 220,205,190 2 ± 1 1 ± 1 1 + 1 1 ± 1 1 + 1 2 +_ 1 
UCHL1 180 47 + 10 59 + 6 66 +_ 7 86 + 11 81 ± 14 78 + 16 
RP1/ l l  (CD45R) 220 1 + 1 1 ± 1 2 ± 1 1 + 1 1 +_ 1 1 ± 1 
Neutrophils were activated or permeabilized as described in the text. Data are expressed as means ± SE of 
specific linear fluorescence intensity mean values of four eparate and independent xp riments 
shown in fig.3, CD45 polypeptides of 180 and 
130-150kDa,  precipitated by either D3/9 or 
UCHL1 MAb (fig.3A,B, respectively), were pre- 
sent in large amounts in fractions 4-6,  correspond- 
ing to the location of tertiary and specific granules. 
As observed, CD45 polypeptides from these frac- 
tions were enriched in the 130-150 kDa compo- 
nent with respect o those corresponding to plasma 
membranes (fig.3A,B, lanes 4 -6  vs 2-3). By con- 
trast, MC5/2 and RP1/ l l  MAb detected CD45 
molecules in neither plasma membrane nor in- 
tracellular membrane fractions (fig.3C and not 
shown, respectively). 
4. DISCUSSION 
In this report, we have analyzed the internal and 
external expression of CD45 polypeptides on 
human neutrophils by using MAb that define four 
distinct CD45 biochemical reactivity patterns on 
PBL. We have found that only those MAb 
recognizing the four CD45 glycoproteins or the 
180 kDa component were reactive with either 
plasma membrane or intracellular CD45 molecules 
from neutrophils, which were always resolved as 
polypeptides of 180 and 130-150kDa. The 
polypeptide material of  about 130-150 kDa 
Fig.3. Immunoprecipitation by anti-CD45 MAb from ~25I-labeled lysates of membranes obtained from resting neutrophil subcellular 
fractions. Membranes from the distinct subcellular fractions, isolated as described in section 2, were solubilized and proteins were 
radioiodinated. Fractions (lanes): (2,3) plasma membrane; (4,5) tertiary granules; (5,6) specific granules; (8) azurophilic r l . 
Samples of each fraction were precipitated by D3/9 (A), UCHL1 (B), or MC5/2 MAb (C), and processed as described in the text. 
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probably was the result of proteolytic degradation 
of the 180 kDa protein. In precipitates with anti- 
CD45 MAb from neutrophil cell lysates tored for 
increasing periods of time, the 180 kDa polypep- 
tide gradually disappeared whereas that of 130- 
150 kDa concomitantly increased (not shown). 
Alternatively, an autoproteolytic a tivity [21] or a 
granule-associated protease activity could also be 
responsible for the putative degradation during 
subcellular fractionation and storage. In this sense, 
our results showed that CD45 reactive material 
from internal granules was enriched in the 
130-150 kDa component. Nevertheless, ince we 
could not prevent his putative degradation with 
protease inhibitors (not shown), the possibility 
cannot be ruled out that the 130-150 kDa 
polypeptide is a normal constituent of human 
neutrophils. 
Interestingly, the expression of the different 
CD45 proteins on resident or circulating leukocyte 
cell subsets appears to be related with the cellular 
maturation stage [13,22]. However, the physiologi- 
cal significance of this selective xpression still re- 
mains unknown. It is important to note that 
human neutrophils only express the biochemical 
reactivity pattern of CD45 proteins defined by the 
UCHL1 MAb, that also reacts with monocytes and 
a subpopulation of T lymphocytes [13,17]. The 
180 kDa CD45 specificity defined by this MAb is 
expressed by a helper inducer subset within the 
CD4 + T cell population [17]. It has also bee 
reported that molecules recognized by UCHL1 
MAb increase their expression on phytohemag- 
glutinin activated mature and naive T cells, sug- 
gesting that this process would be associated with 
activation of post-thymic T lymphocytes [23-25]. 
The biochemical and functional relation between 
the 180 kDa polypeptide expressed by T lym- 
phocytes and neutrophils remains to be deter- 
mined. 
Expression of CD45 proteins on neutrophil 
plasma membranes i up-regulated upon degranu- 
latory stimulation [14]. Since a phosphotyrosine 
phosphatase activity has been recently demon- 
strated for CD45 molecules [4], the change in 
cellular location of this enzymatic activity could be 
crucial to the regulation of the neutrophil activa- 
tion through local alterations in the phosphoryla- 
tion state of phosphotyrosine proteins. As we 
show, the overexpression f CD45 does not affect 
the antigenic and biochemical nature of the CD45 
neutrophil molecules. Such up-regulation is not 
dependent on protein synthesis and occurs rapidly, 
reaching a maximum increase about 15 min after 
addition of stimulus (unpublished), in a similar 
manner to that observed with other leukocyte 
glycoproteins implicated in cellular adhesion func- 
tions (leukocyte adhesion glycoprotein family 
LFA) [18,26]. These proteins mediate cellular ag- 
gregation and leukocyte adhesion to endothelial 
cells [27,28], but the existence of other different 
molecules has also been suggested to be implicated 
in such processes [29-31]. Interestingly, it has been 
recently reported that T lymphocytes from inflam- 
matory infiltrates and those displaying a higher 
capacity to adhere to endothelium are mostly 
UCHL1 ÷ [32]. Furthermore, the interaction of a 
180 kDa CD45 component with cytoskeletal 
elements has also been described [33]. Taken 
together, these observations indicate the possible 
validity of the speculation that CD45 180 kDa 
glycoproteins might be involved in regulation of 
leukocyte adhesive processes by selective 
dephosphorylation f different cellular substrates. 
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